Categories: Public Communication|YervoyMISSISSAUG,a ON and MONTREAL, QC, September 4, 2013Onglyza® (saxagliptin) Achieves Primary Safety Endpoint, Demonstrating No Increased Risk for Cardiovascular Death, Heart Attack or Stroke in SAVOR Cardiovascular Outcomes Trial- SAVOR provides information on cardiovascular safety for Onglyza in the wake of past questions cardiovascular safety of type 2 diabetes treatments - SAVOR is the largest cardiovascular outcomes trial to study a diverse population of type 2 diabetes patients at high risk for cardiovascular events - Onglyza did not meet the primary efficacy endpoint of superiority to placebo - In additional analyses, patients treated with Onglyza had improved glycemic control over two years more... See more text